If you have been following ONEOK (OKE) lately, you might have noticed the stock’s quietly shifting trajectory. With no major headlines or sudden events driving the recent moves, the activity has likely caught the attention of investors who watch for signals in calm waters as much as in stormy seas. Whether this subtle volatility is hinting at a larger story beneath the surface or simply reflecting routine market mechanics, it's the kind of moment that makes you wonder if there is something to be gleaned from the current price action. Looking at the bigger picture, ONEOK’s performance has been mixed. Over the past year, shares are down almost 20%, following a weaker trend that has built up gradually since the start of the year. Still, if you take a step back and view performance across five years, total returns are up substantially. After a strong run over several years, the stock’s recent momentum has clearly faded, and the company’s healthy revenue and income growth have not managed to offset the share price weakness in the shorter term. Now that the dust has settled from last year’s declines, the big question is whether ONEOK is trading at a discount that presents real value, or if the market has already priced in the company’s future prospects.

According to the most widely tracked valuation narrative, ONEOK appears significantly undervalued relative to its fair value, hinting at considerable upside based on current analyst projections.

Persistent growth in global demand for U.S. natural gas and NGLs, driven by increasing international energy needs and continued coal-to-gas switching, supports long-term volume throughput and higher utilization rates across ONEOK's midstream and export infrastructure. This directly underpins future revenue and EBITDA growth.

How does ONEOK's global positioning and expanding infrastructure trigger such a big value gap? The answer lies in bold future earnings projections, growth assumptions, and margin expectations that differ from industry norms. Curious which key financial forecasts put a high price tag on this stock? Get ready to discover the quantitative levers shaping this fair value outlook.

Result: Fair Value of $96.11 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, persistent commodity price volatility and the mounting financial impact of recent acquisitions could quickly challenge even the most optimistic forecasts for ONEOK.

Find out about the key risks to this ONEOK narrative.

Looking at ONEOK through the lens of its price-to-earnings ratio compared to the industry, the stock appears somewhat expensive relative to its peers. This evaluation offers a less favorable perspective than the optimistic fair value estimates. Could this gap reveal hidden risks or overlooked strengths?

See what the numbers say about this price — find out in our valuation breakdown.

Stay updated when valuation signals shift by adding ONEOK to your watchlist or portfolio. Alternatively, explore our screener to discover other companies that fit your criteria.

If you see things differently or like to form your own conclusions from the numbers, it's straightforward to craft and share your personal take on ONEOK in just a few minutes. Do it your way.

A great starting point for your ONEOK research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.

Don’t let your next smart move slip by. Simply Wall Street's latest stock screens can help you spot fresh opportunities that most investors are missing.

Discover budget-friendly shares with potential by using our screen for penny stocks with strong financials: penny stocks with strong financials.

Focus on long-term wealth by searching for dividend stocks with yields above 3% using our top-performing income ideas: 3%;elm:context_link;itc:0;sec:content-canvas\\" class=\\"link \\">dividend stocks with yields > 3%.

Explore the future of artificial intelligence by identifying innovative healthcare companies with our healthcare AI stock screen: healthcare AI stocks.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include OKE.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com